Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies

Author(s): Robert E. Roses, Henry M. Kuerer

Journal Name: Current Cancer Therapy Reviews

Volume 8 , Issue 3 , 2012

Become EABM
Become Reviewer


The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.

Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 29 August, 2012
Page: [182 - 188]
Pages: 7
DOI: 10.2174/157339412802653173
Price: $65

Article Metrics

PDF: 6